Care4Rare is a research project to identify therapeutic leads for rare diseases such as ARSACS. The Foundation is financing the ARSACS portion under the leadership of Dr. Kym Boycott and Dr. Alex MacKenzie from the Children Hospital of Eastern Ontario. Year 2 Summary

The phase II chronic study on the ARSACS mouse with respect to a compound is now at a wrap up stage. The conclusions of the study can be summarized by a problematic delivery of the compound. Therefore, the study will not be pursued further.

The Foundation is looking for researchers in Canada or USA to conduct research on ARSACS. If you are interested in the subject and you would like a new challenge, please contact the Foundation for more information by email at ataxia@arsacs.com

“The use of KO and KI mice, a human fibroblast model and Sacs mini-gene in the search of a treatment for ARSACS”– Dr. Bernard Brais Co-director of the neuromuscular group of the Montreal Neurological Institute and Hospital. “Role of neurofilaments and mitochondria in...

La Fondation est à la recherche de chercheurs/partenaires intéressés à participer à la compétition E-Rare-3 2016. La date limite pour la pré-inscription des soumissions est le 2016-02-01. Pour plus d'information, consultez E-Rare-3 Call for Proposals.

Dr Francesca Maltecca's research project "Investigating the Link Between Impaired Mitochondrial Trafficking and Calcium Dysregulation in SACS/Purkinje Neurons" will be receiving funding from the Foundation. Dr Maltecca is from the Universita Vita-Salute(Milan,Italy)....

Dr. Kalle Gehring's Article "High-Throughput Screening for Ligands of the HEPN Domain of Sacsin" published in the PLOS (Public Library of Science) in the September edition. Dr. Kalle Gehring is a member of the ARSACS research team. PLOS is a non-profit publisher and...

The ARSACS project entitled "PREPARE" and led by Dr. Matthis Synofzik (Germany) has been selected for funding as part of the international competition E-Rare-3 European Research Projects on Rare Diseases. A total of 234 projects were submitted last February and 19...

Dr. Slaven Erceg's research project, one of the projects funded by the Foundation for the 2015-2016 fiscal year, has received coverage in several spanish media. See Press release,or Communidad,or Infosalus, or Valencia.

The Foundation is pleased to announce that eleven research projects have been selected to share over $1.4M in research grants for its 2015-2016 research program. All applications received were evaluated by the Scientific Committee. The Foundation would like to thank...

On June 23, a meeting was held in Montreal between a pharmaceutical company and the ARSACS research team with respect to the outcome of the preclinical trial phase 11 currently underway on the ARSACS mice at the Douglas Institute. The complete results should be known...

A molecular and clinical study of a cohort of 110 Algerian patients with ARSACS has been published on June 12,2015 in the BMC Medical Genetics. See Algerian study.

The meeting of the team of researchers "ARSACS – CIHR" held on June 3 provided an opportunity to share the most recent research results from each lab. See ARSACS meeting.

In February 2015, the Foundation funded a study conducted by Olivier Audet to determine the impact of a regular training program on ARSACS patients. The study shows a significant improvement for 11 of the 13 evaluations of physical fitness and the functional ability....

The preparation required for a preclinical trial with a therapeutic molecule coming from the United States will begin soon. This test will be done on ARSACS mice in Montreal laboratories. This will be the 2nd preclinical trial funded by the Foundation. The results of...

As part of the international competition E-Rare-3 European Research Projects on Rare Diseases, the ARSACS project entitled "PREPARE" led by Dr. Matthis Synofzik (Germany) was selected for phase 2 of the competition. A total of 234 projects were submitted and 51 were...

Anti-Sacsin Antibody now available through Millipore(product # ABN1019). For more information, click Millipore.

Dr. Jonathon Burman, Ph.D. (Research Fellow) will study the role of the Sacsin on human cells. Dr. Burman is part of Dr. Richard Youle's research lab at the National Institutes of Health (NIH) Maryland, USA. See Dr. Burman's project abstract.

Preliminary discussions are under way with an American pharmaceutical company to test a drug for ARSACS (preclinical trial). More information to follow.

A consortium of ARSACS researchers from several countries (Canada, Germany, Netherlands, France, Italy and Turkey) have filed a letter of intent as part of the E-Rare3 competition. More information to follow.

Olivier Audet will present the results of his study at the Congrès de l'Association Québécoise des Sciences de l'Activité Physique – AQSAP Québec 2015 will be held on February 6 and 7 at Laval University. His study, funded by the Foundation, is to determine the impact...

Activities are currently under way to conduct chronic studies on the administration of a drug in ARSACS mice. A preliminary study was done in 2013 and had positive results. This time, the studies will be done over a longer period of time. More details to come.

A video of the panel discussions on ARSACS at the 'CIHR Cafés scientifiques' held in November 2014 is available for viewing. Panel Discussions.